Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers
European Journal of Drug Metabolism and Pharmacokinetics · 2024
DOI: 10.1007/s13318-024-00898-0 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, 2024. Verfasst von Mohamed T Khayyal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. mtkhayyal@gmail.com. Hauptthemen laut MEDLINE: Xanthophylls, Micelles, Cross-Over Studies, Area Under Curve. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Astaxanthin is a naturally occurring carotenoid with high anti-oxidant properties, but it is a very lipophilic compound with low oral bioavailability. This study was conducted to compare the pharmacokinetic parameters of a novel astaxanthin preparation based on micellar solubilization technology, NovaSOL® 400-mg capsules (Test product), and those of astaxanthin 400-mg capsules (reference product), after single oral dose administration to healthy male adults. METHODS: A single oral dose (400 mg equivalent to 8 mg astaxanthin) of test and reference astaxanthin were administered with 240 mL of water to 12 volunteers according to crossover design, in two phases, with a washout period of 1 week in between. Blood samples were collected at hourly intervals for the first 12 h, then at 24.0, 48.0, and 72.0 h after administration. Aliquots of plasma were centrifuged and the clear supernatant was injected into the high performance liquid chromatography-diode array detection (HPLC-DAD) system. Plasma concentration of astaxanthin versus time profiles were constructed, and the primary pharmacokinetic parameters, maximum concentration (Cmax), area under concentration time curve from time of administration (0) to time (t) [AUC0-t] or to infinity ∞, [AUC0-∞], half-life (T½) and time to reach Cmax (Tmax) were calculated. RESULTS: The test micellar astaxanthin reached a Cmax of 7.21 µg/ml after 3.67 h compared to only 3.86 µg/ml after 8.5 h for the reference native astaxanthin. CONCLUSION: Micellar formulation of astaxanthin is capable of producing a high concentration of astaxanthin in plasma in a shorter time, thereby expected to provide faster potential therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. mtkhayyal@gmail.com.
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- Center of Applied Research and advanced Studies (CARAS), Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, ET-11562, Egypt.
- National Center for Radiation Research and Technology, Atomic Energy Authority, Cairo, Egypt.
- AQUANOVA AG, Darmstadt, Germany.
Zitieren
APA
Khayyal, M. T., Teaima, M. H., Marzouk, H. M., -Hazek, R. M. E., Behnam, F., & Behnam, D. (2024). Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers. European Journal of Drug Metabolism and Pharmacokinetics. https://doi.org/10.1007/s13318-024-00898-0
Vancouver
Khayyal MT, Teaima MH, Marzouk HM, -Hazek RME, Behnam F, Behnam D. Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers. European Journal of Drug Metabolism and Pharmacokinetics. 2024. doi:10.1007/s13318-024-00898-0
BibTeX
@article{Khayyal2024,
author = {Khayyal, Mohamed T and Teaima, Mahmoud H and Marzouk, Hoda M and -Hazek, Rania M El and Behnam, Frank and Behnam, Dariush},
title = {Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers},
journal = {European Journal of Drug Metabolism and Pharmacokinetics},
year = {2024},
doi = {10.1007/s13318-024-00898-0}
}
EUVIMED